Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02117362
Title Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Providence Health & Services
Age Groups: adult
Covered Countries USA

No variant requirements are available.